Literature DB >> 16580598

What makes a good anti-inflammatory drug target?

David L Simmons1.   

Abstract

This review focuses on the major, 'successful' target families in inflammation and attempts to identify some of the key features of what makes a good anti-inflammatory target. The review is based on a systematic analysis of approved anti-inflammatory drugs grouped according to their drug-target family. The cytokine family is a drug-dense area. They have yielded and continue to yield a rich stream of drugs. As in other therapeutic areas, G-protein-coupled receptors (GPCRs), also known as seven-transmembrane pass receptors, have provided significant drug targets. In addition, the superfamilies of cell adhesion molecules and co-stimulatory molecules, which have special relevance to immune processes, have begun to provide the first approved drugs and might yield many more. The recent, rapid increase in the number of defined targets in the immune system -- leukocyte surface antigens, cytokines, GPCRs, adhesion molecules and co-stimulatory molecules -- will ensure a rich stream of future anti-inflammatory drug targets.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16580598     DOI: 10.1016/S1359-6446(05)03721-9

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  14 in total

Review 1.  Averting inflammation by targeting the cytokine environment.

Authors:  Manfred Kopf; Martin F Bachmann; Benjamin J Marsland
Journal:  Nat Rev Drug Discov       Date:  2010-09       Impact factor: 84.694

Review 2.  Antibodies against G-protein coupled receptors: novel uses in screening and drug development.

Authors:  Achla Gupta; Andrea S Heimann; Ivone Gomes; Lakshmi A Devi
Journal:  Comb Chem High Throughput Screen       Date:  2008-07       Impact factor: 1.339

Review 3.  P21-activated kinase in inflammatory and cardiovascular disease.

Authors:  Domenico M Taglieri; Masuko Ushio-Fukai; Michelle M Monasky
Journal:  Cell Signal       Date:  2014-05-02       Impact factor: 4.315

4.  2-(2-Arylphenyl)benzoxazole As a Novel Anti-Inflammatory Scaffold: Synthesis and Biological Evaluation.

Authors:  Kapileswar Seth; Sanjeev K Garg; Raj Kumar; Priyank Purohit; Vachan S Meena; Rohit Goyal; Uttam C Banerjee; Asit K Chakraborti
Journal:  ACS Med Chem Lett       Date:  2014-02-17       Impact factor: 4.345

Review 5.  Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases.

Authors:  Yuping Lai; Chen Dong
Journal:  Int Immunol       Date:  2015-11-06       Impact factor: 4.823

6.  Anti-Inflammatory Potential of Ethanolic Leaf Extract of Eupatorium adenophorum Spreng. Through Alteration in Production of TNF-α, ROS and Expression of Certain Genes.

Authors:  Ashim K Chakravarty; Tamal Mazumder; Shankar N Chatterjee
Journal:  Evid Based Complement Alternat Med       Date:  2011-06-16       Impact factor: 2.629

7.  Inhibition of G-protein βγ signaling enhances T cell receptor-stimulated interleukin 2 transcription in CD4+ T helper cells.

Authors:  Evan A Yost; Thomas R Hynes; Cassandra M Hartle; Braden J Ott; Catherine H Berlot
Journal:  PLoS One       Date:  2015-01-28       Impact factor: 3.240

8.  Enantioselective, Convergent Synthesis of the Ineleganolide Core by a Tandem Annulation Cascade.

Authors:  Robert A Craig; Jennifer L Roizen; Russell C Smith; Amanda C Jones; Scott C Virgil; Brian M Stoltz
Journal:  Chem Sci       Date:  2016-08-17       Impact factor: 9.825

9.  Anti-Inflammatory Effects of Vitisinol A and Four Other Oligostilbenes from Ampelopsis brevipedunculata var. Hancei.

Authors:  Chi-I Chang; Wei-Chu Chien; Kai-Xin Huang; Jue-Liang Hsu
Journal:  Molecules       Date:  2017-07-17       Impact factor: 4.411

10.  Gene discovery for the carcinogenic human liver fluke, Opisthorchis viverrini.

Authors:  Thewarach Laha; Porntip Pinlaor; Jason Mulvenna; Banchob Sripa; Manop Sripa; Michael J Smout; Robin B Gasser; Paul J Brindley; Alex Loukas
Journal:  BMC Genomics       Date:  2007-06-22       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.